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Abstract
BED estimates of HIV incidence from cross-sectional surveys are obtained by restricting, to fixed time T, the period over
which incidence is estimated. The appropriate mean recency duration (VT ) then refers to the time where BED optical
density (OD) is less than a pre-set cut-off C, given the patient has been HIV positive for at most time T. Five methods, tested
using data for postpartum women in Zimbabwe, provided similar estimates of VT for C= 0.8: i) The ratio (r/s) of the number
of BED-recent infections to all seroconversions over T= 365 days: 192 days [95% CI 168–216]. ii) Linear mixed modeling
(LMM): 191 days [95% CI 174–208]. iii) Non-linear mixed modeling (NLMM): 196 days [95% CrI 188–204]. iv) Survival analysis
(SA): 192 days [95% CI 168–216]. Graphical analysis: 193 days. NLMM estimates of VT - based on a biologically more
appropriate functional relationship than LMM – resulted in best fits to OD data, the smallest variance in estimates of VT ,
and best correspondence between BED and follow-up estimates of HIV incidence, for the same subjects over the same time
period. SA and NLMM produced very similar estimates of VT but the coefficient of variation of the former was .3 times as
high. The r/s method requires uniformly distributed seroconversion events but is useful if data are available only from a
single follow-up. The graphical method produces the most variable results, involves unsound methodology and should not
be used to provide estimates of VT . False-recent rates increased as a quadratic function of C: for incidence estimation C
should thus be chosen as small as possible, consistent with an adequate resultant number of recent cases, and accurate
estimation of VT . Inaccuracies in the estimation of VT should not now provide an impediment to incidence estimation.
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Introduction
The BED Capture Enzyme Immuno-Assay (BED-CEIA or
simply BED) measures the increasing proportion of anti-HIV-
1 IgG in total IgG following HIV seroconversion [1]. HIV positive
cases are classified as ‘recent’ seroconverters if they have a
normalized optical density (OD) below a given cut-off on the BED
assay. In principle the estimation of HIV incidence, i.e., the rate of
occurrence of new infections, is a straightforward process using
such a test, involving only enumerating the recent infections in a
cross-sectional survey.
In practice, however, application of the BED method has
resulted in over-estimates of HIV incidence [2]. Part of the
problem with the application of the method is that there is no
general agreement on how best to define the total times that
patients spend in the recent state during their lives, let alone how
best to estimate their mean value [3,4].
The situation has clarified recently, however, with the
demonstration that it is neither necessary nor desirable to estimate
the mean recency duration over the whole life of a patient [5,6].
Instead we should estimate the mean time spent in the recent state,
i.e., the mean recency duration, during the time that patients have
been HIV positive for at most some pre-defined time T. In this
paper we investigate a number of approaches to the estimation of
the mean recency duration for the BED method under this
simplified scenario.
In so doing we investigate whether there is an optimum way of
estimating the mean recency duration or whether several
estimating procedures provide similar answers and whether, then,
simple approaches will provide adequate answers. We also ask
how estimates of the mean recency and incidence are affected by
our choice of cut-off and whether these effects differ with our
choice of estimation method.
Since all of the methods investigated below have been used
previously in the literature, we do not in general attempt to
provide formal statistical justification for their use, except where
we have suggested modifications to the methods. Instead we
contrast the resulting estimates in terms of their means and
variances under different sets of input conditions, and then discuss
under what conditions there could be reasons for preferring some
estimators over others.
Methods
Data
Mean recency duration was estimated from data produced
during the Zimbabwe Vitamin A for Mothers and Babies
(ZVITAMBO) Trial, in Harare, Zimbabwe. All details regarding
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the study design, data collection and ethical clearance have been
described previously [2,5,7].
Briefly, between October 1997 and January 2000, 14,110 women
and their babies were recruited within 96 hours of giving birth,
tested for HIV at recruitment and at follow-up visits at 6-weeks, and
3, 6, 9, 12 …. 24-months. All available HIV positive samples from
seroconverting mothers and from mothers who tested HIV positive
at baseline, or at the 12-month visit, were tested by BED: subsets of
these data were used to estimate mean recency duration. The time
distribution of seroconversions during the first 12-months postpar-
tum was also used to estimate HIV incidence [8,9].
Incidence Estimation Using the BED
For BED data obtained from the analysis of cross-sectional
survey data, two independent derivations [5,6] suggest that a
weighted average of the incidence rate over some pre-defined time
T is best estimated by:
I^~
R{eP
(VT{eT)N
ð1Þ
where I^ has units T21, P and N are the numbers of seropositive
and seronegative clients in the sample taken at time T, R the
number of infections classified as recent, e is the probability that a
case tests as a recent infection given that the case has been HIV
positive for time .T, and VT is the mean recency duration for
those cases that have been alive and testing recent by BED while
HIV positive for time # T: VT has the same units as T. R, VT and
e are functions of the pre-set OD cut-off (C). The variance of I^
takes account of uncertainties in the estimates of both VTand e, as
detailed in [6]. When e=0 or, equivalently, when no adjustment is
made for e:
I^0~
R
VTN
ð2Þ
Estimating the Mean Recency Duration
For pre-defined time T and cut-off C, set at levels convenient to
the experimenter, we wish to estimate the mean time (VT ) that a
case spends in the recently-infected state (i.e., with BED optical
density,C) while alive and infected for at most time T: formally
VT may be termed a restricted mean survival time with
VT~E(min (Y ,T)), where Y is the time to crossing C. Without
loss of generality, we take T as one unit of time, specifically one
year for the ZVITAMBO study. Values of both VT and e are
required in order to estimate the incidence from BED data
obtained from cross-sectional surveys. The value of e can be
estimated in a given situation from a sample of cases known to be
HIV positive for time .T. Estimates of VT were obtained using
five different methods:
i) Proportion of recent infections among seroconverters,
r/s [6]. For cases that are HIV negative at time 0 and tested
again at time T, VT=T gives the probability that a seroconverter
tests recent by BED – assuming a uniform distribution of
seroconversion events over [0,T] [6]. It follows that, if s is the
number of HIV positive cases observed at time T, among those
HIV negative at time 0, and r is the number of these
seroconverters that test recent by BED, given an OD cut-off of C:
V^Trs~r=s ð3Þ
Notice that r here is the number of women testing recent at time
T only among women who were HIV negative at baseline,
whereas, more normally as in Equations (1) and (2), R refers to the
number testing recent in a population cross sectional survey.
It has been argued that a good estimate for the mean recency
duration will ensure equality between BED and follow-up
estimates of incidence (I^f ) if both estimates are made over an
identical period (T ), using the same subjects [5]. Thus, taking
I^f~I^0, substituting in (2) and re-arranging, we get the mean
recency duration, given a follow-up incidence rate of I^f :
V^T ,f~
r
I^f N
ð4Þ
with variance given by:
var(V^T ,f )~
r2var(1=I^f )
N2
ð5Þ
where an approximation to var (1=I^f ) is derived using the delta
method.
The ratio
V^T ,j=V^Trs~
r
I^f N
s
r
~
s
NI^f
ð6Þ
is again independent of r and thus of C and has a numerical value
close to one. The ratio r/s in (3) should thus provide an estimate of
the mean recency duration that is close to the estimate that would
be required to ensure equality between follow-up and BED
estimates of incidence.
ii) Linear mixed model (LMM) [1,2]. Transformation of
the unbalanced longitudinal data produces a linear mean structure
and allows, by solving for t, the estimation of the time (w(i) for case
i) between the time at which OD begins to increase above baseline,
Table 1. The numbers of independent BED tests provided by
the 353 women who seroconverted during follow-up in the
ZVITAMBO Trial, when either no exclusion criteria were
applied, or where case were excluded if either there was only
s= 1 sample per case, or the maximum time (tmax) between
the last negative and first positive HIV tests was greater than
120 days.
Inclusion criterion
BED samples per case All tmax #120 days s.1
1 167 –
2 89 28
3 35 25
4 21 17
5 24 17
6 8 5
7 8 7
8 1 1
Total 353 100
doi:10.1371/journal.pone.0049661.t001
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Figure 1. Fits to the BED OD data for a single seroconverting mother from the ZVITAMBO Trial. Predicted values obtained from: A. LMM.
Linear regression of the square root of OD values against log time (t) since the last HIV negative test (Equation (7)). B. NLMM (U). Fitting the non-linear
function given by Equation (8) to the untransformed BED OD data. C. NLMM (L). Fitting the non-linear function given by Equation (9) to the log-
transformed BED OD data. D. Using the fit described in C, but now plotting loge(OD) on the ordinate.
doi:10.1371/journal.pone.0049661.g001
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Figure 2. Fits to the BED OD data for ZVITAMBO mothers providing at least six BED samples following seroconversion. Fitting the
non-linear function given by Equation (9) to the log-transformed BED OD data for 12 different women in the ZVITAMBO Trial who provided either six
or seven separate BED results following seroconversion, and where the time between last negative and first positive HIV tests was at most 120 days.
Plots of loge(OD) against estimated time since seroconversion.
doi:10.1371/journal.pone.0049661.g002
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and the time it reaches the OD cut-off (C) [1,2]. Changing optical
density for each individual i is modeled as:
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ODij
p
~AizBi ln (t
0
ij)zeij ð7Þ
where Ai and Bi are constants containing fixed and random
effects, t0ij is the time at observation j since the last HIV negative
test and the eij are independent and identically distributed normal
errors. The LMM approach to fitting these data studied changes
over time within subjects and for the entire group. Each recency
duration is defined as the time spent in the recent state, with the
upper limit restricted to T. Bootstrap techniques were applied to
these individual estimates to obtain the mean and confidence
intervals for the mean recency duration (V^TL ), with the provisos
noted above.
iii) Non-linear mixed model. (NLMM) [10]. Sweeting et al.
[10] modeled changing BED optical density for each individual i,
at observation j, as:
ODij~aiz(bi{ai) exp ({citij)zeij ð8Þ
where ai, bi and ci are constants, tij is the time since
seroconversion and the eij are independent and identically
distributed normal errors. The date of seroconversion is assumed
to be uniformly distributed between the dates of last negative and
first positive HIV tests. Individual recency durations were obtained
by using an inverse prediction technique [10]. A Bayesian
approach using Markov Chain Monte Carlo (MCMC) methods
is implemented to estimate the posterior distribution of the recency
duration for each individual, with the upper limit restricted to T.
Similarly, the distribution of the mean recency duration is
obtained using the MCMC iterations. The mean recency duration
(V^TNL ) and credibility interval are obtained from this distribution.
This method assumes that the underlying biomarker process
increases monotonically. Due to measurement error, the observed
measurements will fluctuate around the underlying trajectory and
will not increase monotonically.
We investigated a variant of this function:
log (ODij)~aiz(bi{ai) exp ({citij)zeij ð9Þ
where ci.0, ai.bi and the eij are independent and identically
distributed normal errors. This function also approaches an
asymptote for large t and has the further property that it goes to
zero as t R 2‘.
iv) Survival analysis (SA) [9,10]. Assuming no underlying
parametric model for the recency duration, the SA approach is
followed when recognizing the data as being double interval
censored. The exact times of seroconversion and of reaching a pre-
defined OD cut-off are not known, but intervals for each are
obtained from the data. This creates an interval of the shortest and
longest possible recency durations for each individual. Sweeting
et al. [10] used such data to calculate the upper and lower bounds
of the cumulative distribution function for the recency duration.
They found this to be of little practical use and did not pursue the
method to provide mean values of the recency duration.
They also noted that carrying out a univariate survival analysis
of the double interval censored data, as if they were single interval
censored, assumes an incorrect likelihood function. We consider
Figure 3. Mean recency durations, estimated using different methods, as a function of the BED pre-set optical density cut-off (C).
Mean recency durations (with 95% confidence intervals) estimated using: A. Non-linear mixed modeling (NLMM); linear mixed modeling (LMM); the
proportion of recent infections among seroconverters tested at one year postpartum (r/s). B. Survival analysis (SA); graphical analysis (Graph). NLMM
estimates, included in both A and B as a reference, increased quadratically with C: OD=264.4C2+275.3C+17.4 (R2.0.999). The dotted line indicates
the greater variability inherent in the graphical method of estimation.
doi:10.1371/journal.pone.0049661.g003
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an alternative approach where we approximate the time of
seroconversion to be the mid-point between the times of the last
negative and first positive HIV tests. Given that, for our data, the
maximum time between these tests was set at 120 days (average 83
days), the average error in the assumed date of seroconversion
should be small. The data are then single interval censored and
Turnbull’s modification of the Product-Limit Estimator yields a
survival function which, when integrated over [0,T], provides a
mean recency duration (V^TS )and corresponding confidence
intervals. SA has the advantage of having no parametric
assumptions, but the disadvantage that it does not use information
on the shape of the increase in OD with t.
v) Graphical method [1]. For seroconverting cases that
have been HIV positive for less than time T, the mean recency
duration was estimated from a scatter plot of BED OD values and
the time (tS) since seroconversion, estimated here as the mid-point
between the last negative and first positive HIV tests. For a given
choice of C we seek a recency duration (V^TG) that produces an
equal number of cases where: i) tS,(V^TG) and OD$C and ii)
where (V^TG)ƒtsvT and OD,C – i.e., which results in equal
values of the sensitivity and specificity over time T [3].
Data Analysis
Data were analyzed using Microsoft Excel, R version 2.14.1
[11] and WinBUGS 14 [12]. The code used to produce the
NLMM estimates was that used in [10].
Results
HIV and BED Test Results at Baseline and Follow-up
Of 14,110 women recruited, 9562, 4495 and 53 mothers tested
HIV negative, positive and indeterminate, respectively. During
follow-up, 353 of the initially HIV negative mothers were seen to
seroconvert: the numbers of times that each of these cases was
seen, and tested for HIV and for BED optical density (OD), are
shown in Table 1.
At 12-months postpartum, 6829 of the baseline HIV negative
cases were retested: 6595 still tested HIV negative and s=234
tested positive. All of the HIV positive cases were tested using BED
and r=123 of them had an OD,0.8 – i.e., they tested ‘‘recent’’ at
the commonly used OD cut-off. Of the baseline HIV positive
cases, 3010 were seen again at 12-months and all were confirmed
as still HIV positive. Of these cases, 2749 were tested using BED
and 142 of them had an OD,0.8, i.e., tested ‘‘recent’’, despite
having been HIV positive for at least one year.
The r/s estimator used only the above HIV and BED test data
Figure 4. Graphical approach for estimating the mean recency
duration. The graph shows a scatter plot of all BED OD values
obtained from seroconverting women from the ZVITAMBO study,
where the time between the last negative and first positive HIV tests
did not exceed 120 days and where the woman provided at least four
HIV positive samples. Horizontal line marks a pre-set OD cut-off of 0.8;
vertical lines mark a pre-set cut-off of T= 365-days and a line whose
position can be varied until the number of points in rectangles A and B
are the same. Points in the other four rectangles are not used in this
estimating procedure.
doi:10.1371/journal.pone.0049661.g004
Table 2. Mean recency duration for seroconverting
postpartum women in the ZVITAMBO Trial, estimated using
five different approaches.
Method
Mean recency
duration
(95% CI) (days) Coefficient of variation (%)
i. NLMM 196 (188–204) 2.0
ii. LMM 191 (174–208) 4.7
iii. Survival analysis 192 (168–216) 6.4
iv. Ratio r/s 192 (168–216) 6.4
v. Graphical 193 –
The optical density cut-off was fixed at 0.8 for all methods, minimum of two
samples per case were required and the maximum allowable time between the
last negative and first positive HIV tests was 120 days.
doi:10.1371/journal.pone.0049661.t002
Table 3. Mean recency duration for seroconverting
postpartum women in the ZVITAMBO Trial, estimated using
non-linear mixed modeling (NLMM), as a function of the
minimum number of samples (NS) allowable per client and
the maximum period (t0) allowed between the last negative,
and first positive, HIV tests; n denotes the resulting number of
clients included in the test.
t0 (days) NS n Mean recency (95% CrI) (days)
CoV
(%)
80 2 32 176 (165–187) 3.2
80 3 27 179 (166–191) 3.5
80 4 23 193 (179–207) 3.7
120 2 100 196 (188–204) 2.0
120 3 71 199 (191–208) 2.2
120 4 47 194 (183–205) 2.9
160 2 109 193 (185–200) 2.0
160 3 78 196 (188–204) 2.1
160 4 51 192 (182–202) 2.6
The optical density cut-off was fixed at 0.8 for all estimates. The coefficient of
variation (CoV) is defined as the standard error of the estimate divided by the
mean, expressed as a percentage.
doi:10.1371/journal.pone.0049661.t003
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from baseline and twelve months. The other four methods used all
of the qualifying data available from follow-up. For mixed effects
modeling and survival analysis a minimum of S=2 samples per
patient are required: there were 186 such cases (Table 1). To
minimize uncertainty regarding the time of seroconversion it is,
moreover, necessary to limit the maximum time (tmax) allowed
between last negative and first positive samples [2]: initially tmax
was set at 120 days. The above selection criteria resulted in a
sample of 100 women (Table 1), who were used to compare the
performance of the LMM, NLMM, SA and graphical estimators.
Sensitivity of the estimates of VT to these selection criteria was
investigated by varying S between 2 and 4 and tmax between 80
and 160 days. Estimates were obtained for OD cut-offs (C) ranging
from 0.4 to 1.2.
Estimates of the Mean Recency Duration
i) Estimates using r/s. Previously published survival anal-
ysis of the follow-up HIV test data provided an estimate of the
probability (J ) of seroconverting during the first year postpartum
of 3.4% (95% CI: 3.0%–3.8%) or, equivalently, an instantaneous
incidence rate (I) of 3.46% per year (95% CI: 3.05%–3.87%),
approximating I from I=2ln(12J ), and using the approximation
that the incidence is constant over the interval [0,T] [8,9].
Of the cases testing HIV negative at baseline, and then tested
again at 12-months, N=6595 tested HIV negative. Seroconver-
sion was detected among s=234 of these cases, and r=123 of
these tested recent by BED when using a cut-off of C=0.8. For this
cut-off it is confirmed that the mean recency duration provided by
Equations (3) and (4) are closely similar, as expected:
(V^Trs )~
r
s
~
123
234
~0:527 years~192 days
½95%CI 168{216 days
(V^T ,f )~
r
I^f N
~
123
0:0346|6595
~0:540 years
~197 days ½95%CI 174{220 days
Accordingly, further reports will contrast only (V^Trs ) to the
estimates provided by the regression, survival analysis and
graphical approaches.
ii) & iii) Linear and non-linear mixed modeling. Figure 1
provides an illustration of the fits achieved using the functions in
Equations (7), (8) and (9) to data for the single ZVITAMBO
seroconverting woman who provided BED samples at eight
separate time points post-seroconversion. While all of the functions
provide reasonable fits to these data, Equation (7) predicts that OD
R ‘ both as t R ‘, and as t R 0 (Figure 1A). Equation (8)
matches biological observations better, in that the OD approaches
a finite asymptote as t R ‘. However, OD R 2‘ as t R 2‘ so
that the predicted value of the OD can be negative for small
positive values of t (Figure 1B). This property could be avoided by
insisting that bi.0, but the function still goes to2‘ as tR2‘ and
has an inappropriate shape in the neighborhood of t=0. Equation
(9) has the property of approaching finite asymptotes for both large
and small times: ODR exp(ai) as tR ‘, and ODR 0 as tR 2‘.
Unlike Equation (8) therefore, it never predicts negative values of
OD and provides better fits to the data in the neighborhood of
t=0 (Figure 1C), matching the observation that there is a delay,
following seroconversion, in the increase in BED optical density.
Figure 1D shows the same fit as for Figure 1C but plotting
loge(OD) on the ordinate.
The likely form of the increase of the BED optical density with
time since seroconversion can only be well judged from results for
those individuals who are seen a number of times over an extended
period. Figure 1D and Figure 2 shows plots for all thirteen cases in
the ZVITAMBO data set where seroconverting subjects provided
at least six independent BED results, and where the time between
last negative and first positive HIV tests was at most 120 days. All
cases were followed up for more than a year and 8/13 followed for
more than 18 months, and in all cases Equation (9) provided a
good fit to the data for individual clients (Figure 2). For 33/47
(70%) of cases where there were at least four BED results,
Equation (9) provided a better fit to the data than Equation (8):
accordingly, results are only presented below for fits using
Equation (9).
BED data for all qualifying seroconverting cases were analyzed
using LMM and NLMM. For the NLMM method, estimates of
(V^T ) increased quadratically for C varying between 0.4 and 1.2.
For C,0.6 the LMM estimates were significantly lower than those
from the NLMM, but there were no significant differences
between the estimates for C=0.6–1.2 (Figure 3A). The r/s
estimates did not differ significantly from either the LMM or
NLMM estimates for C#1.0, although the point estimates were
consistently lower than the NLMM estimates and diverged
increasingly from them for C.1.0. The major differences between
the estimators lay in the coefficient of variation (CoV, i.e., the
standard error divided by the mean), which was, on average, 2.3
Figure 5. The relationship between the long-term false-recent
rate (e) and the pre-set optical density cut-off (C) in the
ZVITAMBO Trial. The value of e was estimated as the proportion of
cases with a BED OD,C among women tested at T=12-months
postpartum, given that they had previously provided a positive HIV test
at baseline. Error bars indicate the 95% confidence intervals.
doi:10.1371/journal.pone.0049661.g005
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and 3.2 times as high for the LMM and r/s estimates, respectively,
as for the NLMM estimates.
iv) Survival analysis. For estimates at each C#1.0 there
were negligible differences (on average 1.9%) between the SA and
NLMM estimates (Figure 3B). The average CoV for the SA
estimate was, however, .3 times as high as for the NLMM
estimates.
v) Graphical method. Figure 4 provides an example of the
use of this method. For a given choice of the OD cut-off, C, the
vertical line, shown at t=193 days in Figure 4, is moved along the
Figure 6. HIV incidence, estimated using BED, with the mean recency duration estimated using four different methods. HIV incidence
(with 95% confidence intervals) among women during their first year postpartum in the ZVITAMBO Trial, calculated using estimates of the mean
recency duration from non-linear mixed modeling (NLMM), linear mixed modeling (LMM), survival analysis (SA) and graphical analysis (Graph).
doi:10.1371/journal.pone.0049661.g006
Figure 7. HIV incidence, estimated using BED, with the mean recency duration estimated using five different methods. HIV incidence
(with 95% confidence intervals) in women during the period prior to their recruitment into the ZVITAMBO Trial. A. Non-linear mixed modeling
(NLMM); linear mixed modeling (LMM); survival analysis (SA). B. The proportion of recent infections among seroconverters tested at one year
postpartum (r/s); graphical analysis (Graph). Results for NLMM included for comparison.
doi:10.1371/journal.pone.0049661.g007
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time axis until the numbers of points in rectangle A (those cases
that have been infected for at least t days, but less than T=365
days and test as recent infections, with BED OD,C) is the same as
those in rectangle B (those cases that have been infected for a
period less than t, but test as long-term infections with BED
OD$C).
Whereas it was not possible to provide confidence intervals for
this simple method the estimates of VT are markedly more
variable than those provided by the LMM, NLMM and SA
methods (Figure 3A, B). This variability, and the approximately
step-wise increase in VT with increasing C, results from the regular
timing of follow-up visits in the ZVITAMBO Trial, which
produced approximate vertical alignment of many of the readings
in Figure 4. This effect was particularly noticeable for times close
to seroconversion.
At the commonly used cut-off of C=0.8 the mean of the
estimates from all five methods was 193 days (range 191–196
days), with all estimates differing by,2% from this figure and with
an average deviation of 0.8%. None of the four estimates for which
it was possible to provide 95% confidence intervals differed
significantly from each other (Figure 3, Table 2). The CoV for the
NLMM estimate was, however, less than a half of that for the
LMM estimates and less than one third of that for the SA and r/s
estimates (Table 2).
Sensitivity of the Estimates of VT to Data Selection
Estimates of the mean recency duration were fairly insensitive to
the way in which data were selected. When the minimum
allowable number of samples per client was varied between 2 and
4, and tmax between 80 and 160 days, the estimates of VTestimated
using NLMM differed by at most 8% from the mean of the
estimated values (Table 3).
Variation of the False Recent Rate with the OD Cut-off C
Whereas we have, for completeness, examined the way in which
various estimators perform over a large range of C, it is also clear
that the long-term false-recent rate (e) increases with C. In the case
of the ZVITAMBO Trial, e increases quadratically with changes
Figure 8. Variability in BED HIV incidence estimates as a
function of optical density cut-off (C). The coefficient of variation
for BED HIV incidence estimates obtained using the ZVITAMBO baseline
data, as a function of the pre-set optical density cut-off (C). Incidence
calculated using Equation (1) with values of VT estimated by NLMM.
doi:10.1371/journal.pone.0049661.g008
Figure 9. Distribution of BED optical density among women at recruitment into the ZVITAMBO Trial.
doi:10.1371/journal.pone.0049661.g009
Estimating the Mean Recency Duration
PLOS ONE | www.plosone.org 9 November 2012 | Volume 7 | Issue 11 | e49661
in C between 0.1 and 1.5 (Figure 5). Given that a central aim of
estimating procedures such as BED is to minimize the value of e, it
will make sense to use the lowest value of C consistent with other
considerations (see below).
Incidence Estimates as a Function of C and the Mean
Recency Estimation Method
1. Incidence over the first 12-months postpartum. BED
data from the ZVITAMBO Trial, for women testing HIV positive
both at baseline and at 12-months postpartum, were used to
estimate e. Data for these cases cannot therefore be used to obtain
BED estimates of incidence over this period, since this incidence
estimate, obtained from Equation (1), involves using the estimated
value of e.
BED estimates of the incidence over this period can, however,
be obtained legitimately via Equation (2), which does not involve e,
as long as we use only the BED data for seroconverting women
who tested HIV positive at 12-months postpartum. It is then
possible to compare the follow-up estimate of incidence (I^f ), shown
as a horizontal line in Figure 6, with estimates arising from
Equation (2) for varying values of C, and the appropriate values of
VT , obtained using different estimators. Incidence estimates
appropriate to the r/s estimate of VTare not shown since these
are, as evident from Equation (6), a constant multiple of I^f .
For all values of C tested, the NLMM estimates of incidence
showed the smallest deviation from the follow-up estimate of
I^f =3.46%, varying only between 3.23% and 3.50%: the SA and
NLMM estimates were closely similar for all C #1.0. For C=0.8,
0.9 and 1.0 incidence estimates arising from the use of all methods
differed from each other, and from I^f , by amounts that were small
compared to the size of the confidence intervals. For C,0.8 the
LMM and graphical methods varied more substantially from
NLMM and SA estimates (Figure 6).
Despite the differences in CoVs between the estimates of VT
arising from the NLMM, LMM and SA methods, there was little
difference between the sizes of the confidence intervals for the
incidence estimates. The sizes of these latter intervals are thus
dominated by counting errors arising from the use of the incidence
estimator defined by Equation (2).
2. Incidence over the year prior to birth. The way in
which our choice of C, and thus of VT and e, affects incidence
estimates can also be tested using the ZVITAMBO baseline BED
data since these data were not used in the estimation of either VT
or e. In this case, however, there is no follow-up incidence estimate
for comparison, since baseline marked the first time that any of the
ZVITAMBO subjects had been seen in the study.
The contrasts between estimating methods seen in the
postpartum incidence estimates are, as expected, largely repeated
for the baseline analysis (Figure 7) with the graphical method
showing the greatest variability with changes in C, and with
differences between the estimates from other methods all small by
comparison with the size of the confidence intervals.
For the NLMM method, which produces estimates of VT with
the smallest CoVs, the CoVs of the resulting incidence estimates
also change in a regular manner with increasing C and show a
minimum value for C,0.8 (Figure 8). That is to say that the value
of C commonly used in the application of the BED method is also
associated with the smallest coefficient of variation.
The consistent trend in the baseline HIV estimates with changes
in C are different from those seen in the 12-months postpartum
results (cf Figures 6 and 7) where the NLMM estimates of
incidence were largely independent of C. The source of the
variation in the baseline estimates appears to lie in the distribution
of the baseline optical density data (Figure 9), which show a small
local peak for C in the region 0.6–0.8, and a sharp increase in
frequency at C<1.2. Any particular choice of C results in the
estimation of incidence over a particular time period prior to
sampling and the distribution of BED optical density in Figure 9
suggests that incidence is not uniform over the period leading up to
parturition.
Discussion
Which Estimator?
For C in the neighborhood of 0.8 there is little difference
between the values of VT arising from any of the five estimators
tested here. However, at all values of C tested, NLMM estimates of
VT had markedly smaller variance than the LMM, SA and r/s
estimates. As such the NLMM method provides the best available
approach for estimating VT , for data sets such as those from the
ZVITAMBO study where there is sufficiently detailed information
to support meaningful regression analysis. Only the NLMM and
LMM methods use information on the changes in BED optical
density with time since seroconversion and, accordingly, provide
estimates with lower variance. The NLMM is markedly superior to
the LMM in this regard, being based on a more appropriate
functional relationship, with sensible limits for large and small
times post-HIV infection. This ensures better fits to the data and
markedly smaller variation than for the LMM. NLMM should
accordingly always be used in preference to LMM.
Estimates of VT from the simple graphical method show the
greatest variability and, as demonstrated above, are strongly
dependent on the time distribution of the seroconversion events.
There are, moreover, methodological objections to the use of the
method: the data involve repeated measurements from a number
of individuals, and each measurement is used to define a
probability. The data are thus clearly correlated; for example if
an individual’s data point is ‘‘false recent’’, the next is also likely to
be ‘‘false recent’’. Moreover, measurements become less frequent
with increasing time since last negative HIV test. For all of the
above reasons, the graphical method should be used, if at all, only
to provide first approximations of VT .
The r/s method is dependent on the assumption of a uniform
distribution of seroconversion events across the period [0,T] and,
as is evident from Figure 9, there can sometimes be serious
violations of this assumption. On the other hand, it is noteworthy
that the baseline incidence estimates (Figure 7) from the r/s and
the NLMM methods were closely similar and showed the same
pattern of changes as C was varied between 0.4 and 1.2. Moreover,
in situations where follow-up of individual seroconverting cases is
not as extensive as in the ZVITAMBO Trial, the relative
advantage of regression approaches for the estimation of VTwill
be diminished and the r/s method would provide a reasonable
alternative.
Our findings support previous work suggesting that the use of
SA will be problematic for estimating VT [10]. Even when we used
an approximation, which under-estimates the variance of the
estimate, the coefficient of variation for the SA estimates was
markedly larger than that for the NLMM method. As with the r/s
method, however, the relative advantage of the NLMM method
will be reduced in the situation where there is limited follow-up of
individual clients. We checked this by trimming the ZVITAMBO
data to exclude, for each client, all but the first BED sample and
the sample taken closest to 12-months postpartum. The SA
estimate derived using these data differed by ,2% from the
estimate obtained using the full data set, and the coefficient of
variation was only marginally larger. The NLMM method does
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not provide a meaningful confidence interval with these minimal
data.
Which Cut-off?
For values of the OD cut-off between C=0.6 and 1.2 the BED
estimates of incidence over the 12-months postpartum period,
obtained using the NLMM estimates of VT , accord closely with
the follow-up estimate of about 3.46% per year. These results
provide strong support for this method of estimating VT , but do
not suggest which cut-off should be preferred. This question is
better answered by considering the BED estimates arising from the
ZVITAMBO baseline data – which mirrors more closely the
cross-sectional surveys encountered in practice, where there tends
to be a preponderance of cases with long-term infections. It is then
necessary to adjust the BED incidence estimates for the long-term
false-recent cases, calculating incidence using Equation (1).
The choice of cut-off is then decided by a trade-off of the
advantages of increasing C such that we observe a greater number
of recent cases (R), and decreasing C such that we reduce the value
of e (Figure 5). The net result of such changes sees the CoV of the
baseline incidence estimates showing a well-marked minimum
(Figure 9) suggesting that there is no reason to change from the
value of C=0.8 currently in common use.
Which Incidence Estimate?
Notwithstanding the results of the previous section, the NLMM
estimates of baseline HIV incidence in Figure 9 vary between
4.5% and 6%, depending on the chosen value of C. In
understanding the reasons for this variation it is important to
remember that, as C is increased, HIV incidence is averaged over
progressively longer periods. Moreover, two independent things
are happening: i) VT is changing, in a manner that is determined
by the properties of the test, and is independent of the distribution
of the BED OD values in the cross-sectional sample being
analyzed: ii) The number of cases counted as recent is changing, at
a rate which is a function of the pattern of seroconversions prior to
the sampling time.
Thus, with reference to Figure 9, the rate of accumulation of
cases classified as recent becomes progressively more rapid as C
increases to 0.6, and then progressively less rapid for C increasing
between 0.6 and 1.2. These changes are reflected in changes in
HIV incidence with C (Figure 7), consistent with the idea that the
rate of acquisition of new infections was not constant over the
period prior to a woman’s enrollment in the ZVITAMBO Trial.
This is unsurprising given that enrollment occurred within 96
hours of parturition, so all women were in the same synchronized
physiological state and BED data are reflecting events during the
preceding pregnancy. Indeed, since C=1.2 corresponds to
VT,260 days (Figure 3), just short of the approximate mean
duration of human gestation, the distribution of BED values for C
between 0 and 1.2 basically reflects events during most of
pregnancy.
The results in Figure 7 are consistent with the idea that
acquisition of HIV infection is relatively low shortly before birth. It
is not unreasonable to think that sexual activity, and thus the risk
of HIV infection, is reduced at this late stage of pregnancy,
compared with the middle stages of pregnancy. Similarly, the
sudden jump in frequency at C=1.2 coincides approximately with
the time that the women became pregnant – which is the only time
that we can be absolutely certain that they had all had unprotected
sex and were thus at risk of HIV infection.
On the above interpretation, the results in Figure 8 reflect true
changes in the pattern of HIV infection in the year prior to birth
for women in the ZVITAMBO Trial. Similar situations are likely
to occur in other sampling scenarios. Most women making a first
antenatal clinic visit, for example, are likely to be at a similar stage
of pregnancy, and seroconversion events in the year prior to the
test may be expected to be distributed in a distinctly non-uniform
way.
Limitations
We caution that the present study is based on the application of
various methods to a single set of data, all derived from
postpartum women, from a single city in Zimbabwe and all
infected with a single clade of HIV. The results apply, moreover,
only to the BED method. Similar studies are needed to establish
the extent to which our results can be generalized in other settings
and using other bio-marker methods.
Conclusion
The estimation of the mean recency duration for cases which
have been HIV positive for some defined finite period T proves
much less problematic than previous attempts to estimate the life-
time mean recency duration [1,2,3]. The estimation of mean
recency durations should not thus be seen as a major obstacle to
the use of biomarker methods for estimating HIV incidence,
providing that good care is taken with sample collection and
analysis. The more serious problems lie in: (i) accurately estimating
the false-recent rate for every population where a particular
method is being used: (ii) the development of bio-marker methods
with markedly lower false-recent rates than those typical of the
BED.
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